An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a closely watched late-stage trial, according to results released Sunday. When combined with … [+7253 chars]Read More
A hotly debated lung cancer drug cut the risk of death by 34 in a latestage trial in China CNBC
